Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 20:14:1187870.
doi: 10.3389/fendo.2023.1187870. eCollection 2023.

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade

Taymeyah Al-Toubah  1 , Jonathan Strosberg  1 , Julie Hallanger-Johnson  2 , Ghassan El-Haddad  3   4
Affiliations
Review

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade

Taymeyah Al-Toubah et al. Front Endocrinol (Lausanne). .

Abstract

Targeted radionuclide therapy plays an increasingly important role in managing endocrine-related tumors and significantly advances the therapeutic landscape for patients with these diseases. With increasing FDA-approved therapies and advances in the field, come an increased knowledge of the potential for long-term toxicities associated with these therapies and the field must develop new strategies to increase potency and efficacy while individualizing the selection of patients to those most likely to respond to treatment. Novel agents and modalities of therapy are also being explored. This review will discuss the current landscape and describe the avenues for growth in the field currently being explored.

Keywords: endocrine; neuroendocrine; paraganglioma; pheochromocytoma; radiopharmaceutical.

PubMed Disclaimer

Conflict of interest statement

GE-H: Novartis, Bayer, Boston Scientific, Terumo Consult; JH-J: HRA Pharma Consult. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. . Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med (2017) 376:125–35. doi: 10.1056/NEJMoa1607427 - DOI - PMC - PubMed
    1. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. . Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw (2021) 19:839–68. doi: 10.6004/jnccn.2021.0032 - DOI - PubMed
    1. Van Der Harst E, De Herder WW, Bruining HA, Bonjer HJ, De Krijger RR, Lamberts SW, et al. . [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and Malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 86:685–93. doi: 10.1210/jcem.86.2.7238 - DOI - PubMed
    1. Hennrich U, Kopka K. Lutathera((R)): the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharm (Basel) (2019) 12. doi: 10.3390/ph12030114 - DOI - PMC - PubMed
    1. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. . The 2019 WHO classification of tumours of the digestive system. Histopathology (2020) 76:182–8. doi: 10.1111/his.13975 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources